Project Grant R01CA312510
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $742K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02142, USA
Similar Awards
- Federal Grant Award Summary The Broad Institute of MIT and Harvard received a $443,564 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on September 2, 2025, with completion by August 31, 2027. The award supports the development of a novel cancer immunotherapy platform utilizing engineered commensal skin bacteria to stimulate tumor-specific T cell immunity. The research focuses on leveraging Staphylococcus epidermidis, a naturally...
- Federal Grant Award Summary The National Cancer Institute awarded Harvard Medical School a $237,023 Project Grant under the Cancer Biology Research program (CFDA 93.396) beginning March 13, 2026, with completion targeted for February 28, 2029. This award supports the development and application of high-throughput tools designed to track the fate of prematurely terminated transcripts in cancer cells, specifically focusing on alternative polyadenylation (APA) events that drive oncogenic mechanisms...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $3.74 million Project Grant from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), awarded on August 21, 2025, with a completion date of August 20, 2029. The grant supports mechanistic research investigating the role of CCL5 chemokine in antigen-specific T cell responses within head and neck squamous cell carcinomas (HNSCCs)....
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $901,205 to Boston Children's Hospital under the Cancer Treatment Research program (CFDA 93.395) effective July 3, 2025, with a completion date of June 30, 2032. This research initiative focuses on identifying genome-wide changes in gene expression during early tumorigenesis and metastatic progression to improve immunotherapy efficacy. The project leverages genetically engineered mouse models...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $795,544 Project Grant to the Broad Institute of MIT and Harvard under the Cancer Cause and Prevention Research program (CFDA 93.393) for the period August 1, 2025 through July 31, 2027. The grant supports the development of computational methods for profiling the cancer virome and analyzing microbial strain genetics from shotgun metagenomes and metatranscriptomes. The primary deliverables include novel algorithmic...
- Federal Grant Award Summary The National Cancer Institute awarded University of California, San Diego a $699,929 Project Grant on June 20, 2025, under the Cancer Treatment Research program (CFDA 93.395) to enhance immunotherapy response in human papillomavirus negative head and neck squamous cell carcinoma (HPV-HNSCC). The project, which extends through May 31, 2030, focuses on improving dendritic cell (DC) migration to draining sentinel lymph nodes to enhance the efficacy of programmed...
- Federal Grant Award Summary Beth Israel Deaconess Medical Center, Inc. received a $846,982 Project Grant from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) awarded on August 1, 2025, with an ultimate completion date of July 31, 2032. This seven-year research initiative focuses on understanding the role of innate immunity and epigenetic memory in checkpoint immunotherapy for cancer treatment. The project investigates how the PD-1 (programmed death-1) receptor and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $650,597 Project Grant to the University of California, San Diego under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026 through March 31, 2031. This research project investigates the role of B-cells in durable complete responses to checkpoint blockade immunotherapy (CBI) in head and neck squamous cell carcinoma (HNSCC). While response rates to CBI in HNSCC remain generally low,...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts General Hospital a $659,201 Project Grant effective June 1, 2026 through May 30, 2031 under the Cancer Treatment Research program (CFDA 93.395). This award supports research investigating the integrated stress response (ISR) in glioblastoma (GBM) pathogenesis and therapeutic response. The project focuses on understanding how the interplay between phosphorylated eukaryotic translation initiation factor 2A...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...